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Anti-malarial drugs are now mainly deployed as combination therapy (CT), primarily as a mechanism to prevent or
slow the spread of resistance. This strategy is justified by mathematical arguments that generally assume that drug
‘resistance’ is a binary all-or-nothing genetic trait. Herein, a pharmacological, rather than a purely genetic, approach
is used to investigate resistance and it is argued that this provides additional insight into the design principles of
anti-malarial CTs. It is usually suggested that half-lives of constituent drugs in a CT be matched: it appears more
important that their post-treatment anti-malarial activity profiles be matched and strategies identified that may
achieve this. In particular, the considerable variation in pharmacological parameters noted in both human and
parasites populations may compromise this matching and it is, therefore, essential to accurately quantify the
population pharmacokinetics of the drugs in the CTs. Increasing drug dosages will likely follow a law of diminishing
returns in efficacy, i.e. a certain increase in dose will not necessarily lead to the same percent increase in efficacy. This
may allow individual drug dosages to be lowered without proportional decrease in efficacy, reducing any potential
toxicity, and allowing the other drug(s) in the CT to compensate for this reduced dosage; this is a dangerous
strategy which is discussed further. Finally, pharmacokinetic and pharmacodynamic drug interactions and the
role of resistance mechanisms are discussed. This approach generated an idealized target product profile (TPP)
for anti-malarial CTs. There is a restricted pipeline of anti-malarial drugs but awareness of pharmacological design
principles during the development stages could optimize CT design pre-deployment. This may help prevent changes
in drug dosages and/or regimen that have previously occurred post-deployment in most current anti-malarial drugs.
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The benefits of using a combination of drugs to treat in-
fectious diseases has been recognized since the days of
Laveran [1] and Ehrlich [2] who used combination therapy
(CT) with dyestuffs to treat trypanosomiasis. Drug CTs
are now standard policy for treating human immunodefi-
ciency virus (HIV) infections, tuberculosis (TB) and mal-
aria. In the case of TB and HIV, the use of CT was driven
by clinical necessity as patients routinely failed treatment
with monotherapies. The use of CTs to treat falciparum
malaria, currently in the form of artemisinin-based com-
bination therapy (ACT), rests on a different justification.
Most of the partner drugs in ACT are clinically effective
as monotherapies, especially when first deployed, so the* Correspondence: hastings@liv.ac.uk
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article, unless otherwise stated.use of anti-malarial CTs is primarily justified as a public
health strategy to delay or even prevent the onset of resist-
ance (e.g. [3], recently reviewed in [4]). There is consider-
able concern about the possible onset of artemisinin
resistance, particularly in South-East Asia [5-9] and its
long-term threat to the future of ACT (e.g. [10-14]). Sev-
eral new anti-malarial drugs are in the developmental
pipeline [15,16] so new forms of CT will have to be con-
sidered. Herein, the design principles underlying anti-
malarial CTs are discussed. Clearly identifying desirable
properties of constituent drugs in an anti-malarial CT
may well help guide the developmental pathway and stop/
go decision-making process of anti-malarials currently
under development [17].
Previous models demonstrating the benefits of CT in
delaying the onset of resistance largely assumed thatCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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else completely resistant (discussed further in [4]). The
first type of model, the ‘basic rationale’ [4] considers
how new mutations enter the malaria population. As-
suming the mutation rate to resistance to each drug is
10-9, then the chance of any individual parasites being
spontaneously resistant to both drugs in a CT is vanish-
ingly small (i.e. 10-18). Thus, new mutations should enter
the parasite population extremely rarely (note, however,
the implicit assumption that resistant mutations only
enter the population through drug treatment of the
asexual biomass of typically about 1011 to 1012 parasites
per patient [18]; discussed in more detail in [4]). The
second type of model investigates the dynamics of resist-
ance once it has entered the malaria population. For ex-
ample, models of a two-drug CT typically assume that
resistance to each drug is encoded by a different, single
locus with alleles classified as resistant (R) and sensitive
(S). This gives rise to four 2-locus haplotypes that can be
designated SASB, RASB, SARB and RARB, where subscript
denotes resistance status to drug ‘A’ or ‘B’ respectively.
Consequently, infections of types SASB, SARB and RASB
are always killed by CT treatment while only RARB sur-
vives. This strict dichotomy of ‘resistant’ versus ’sensi-
tive’ forms is useful for elucidating the general principles
underlying CT design but is not a particularly realistic
representation of treatment outcome which is known to
depend not just on parasites genotype, but on other fac-
tors such as immunity and drug dosage [19]. In addition,
these types of models can only demonstrate the broad
benefits of CT but they cannot provide information
about the optimal designs of these CTs. The subtleties of
how resistance evolves may be complex (for example,
artemisinin resistance may be restricted to specific parts
of the parasite life cycle [20]) and are discussed elsewhere
[4,21]. This manuscript will ignore how resistance actually
arises, will simply assume that it is inevitable, and will
focus on considering how pharmacological modelling can
help design CTs that are robust to increasing levels of
parasite resistance entering the parasite population.
A more nuanced approach to resistance/sensitivity can
be achieved using pharmacokinetic/pharmacodynamic
mechanism-based modelling of drug treatment (recently
reviewed in [22]). In this context of the pharmacology of
malaria treatment, pharmacokinetics (PK) describes how
drugs are processed by the human body, e.g. the drug half-
life, while pharmacodynamics (PD) describes how the drug
affects the parasite e.g. the drug concentration producing
half the desired effect (IC50). There are potentially several
different mechanisms and models of PD depending on
how the drug acts: some drug actions may best be
described by the maximum concentration reached, the
times above a certain concentration, or the extent to
which a drug accumulates at the target site. A recentreview and access to the literature is provided in [23]
but here, for simplicity, the discussion assumes anti-
malarial drugs can be best described by standard mod-
elling [22] as previously applied to malaria drug action
(see below). The technique can be summarized as fol-
lows. The drug concentration profile after treatment is
tracked using PK modelling while the sensitivity of the
parasites to the drugs is defined by its PD parameters.
The drug concentration at any time post-treatment
can, therefore, be translated into a parasite kill rate en-
abling change in parasites numbers post-treatment to
be tracked in order to find whether the parasites are
eventually eliminated, or whether they survive treat-
ment. Critically, this strategy allows researchers to de-
fine ‘resistant’ parasites in mechanistic, PD, terms such
as increased IC50 rather than simply assuming they are
completely insensitive to the drug. The fate of the ‘resist-
ant’ parasites can then be investigated in the context of all
the other factors known to affect patient outcome; typical
examples are the pharmacological environment parasites
encounter during treatment (derived from varying patient
PK parameters, e.g. drug elimination rate), the patient’s
adherence to treatment and so on. This approach has
already been applied to malaria [24-27] and recent work
[28-30] has focussed on developing the technical meth-
odology to allow for multiple drug doses, combination
therapies and drug conversion processes. A parallel
data-driven agenda has investigated the nature and extent
of variation in the PK/PD parameters and extension to
real-life deployment such as age- or weight-based dosing
bands and the impact of poor adherence to the recom-
mended regimens [30]. Unlike models based on sensitive/
resistance dichotomy, these PK/PD models do throw light
on what properties define a good CT and herein it is ar-
gued that PK/PD considerations can usefully contribute to
the rational design of CTs.
Key pharmacological considerations for potential
combination therapies
There are six distinct considerations that must be addressed
in the design of CT which will each be addressed in turn.
1. The half-lives and activity profiles of constituent drugs
It has long been realized [31] that a mismatch in half-
lives will leave the drug with the longer half-life to per-
sist as a vulnerable monotherapy (Figure 1) because
new infections emerging from the liver (or inoculated
by the mosquito in the case of drugs that are active
against liver stages such as atovaquone) need only be resist-
ant to a single drug to survive. This effect constitutes one
of the three main drivers of anti-malarial drug resistance
[4]. Therefore, a key recommendation in CT design is
that the drug half-lives should be matched (e.g. [32]) but
this argument warrants further examination.
Figure 1 The consensus view that drugs in a CT should have matching half-lives [32,33]. (A) The constituent drugs have very different
half-lives (as in the current generation of ACT) leaving the ‘blue’ drug to persist as a vulnerable monotherapy for an extended period of time
post-treatment after the ‘red’ drug concentration has decayed to sub-therapeutic concentrations. (B) The constituent drugs have roughly similar
half-lives meaning they should, in principle (but see main text), provide mutual protection post treatment. [Figure 1 was constructed using simple
PK/PD models and their corresponding equations [26,29]. Parameter values for the two drugs were as follows: Dose is 11 mg/kg; volume of distribution
is150 L/kg. Elimination rates per day were 0.03 for ‘blue’ and 0.07 for ‘red’ (equivalent to half-lives of 23.1 and 9.9 days, respectively) in (A) changing to
0.032 for ‘red’ in (B) (equivalent to half-life of 21.7 days)].
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matching is more subtle because mutual protection be-
tween the drugs depends on there being active concen-
trations of both drugs simultaneously. It, therefore,
appears more important that drug anti-malarial activity
profiles post-treatment are the critical factors to be
matched, rather than simply their half-lives. The activity
profile post-treatment depends on three factors, the drug
half-lives, the dosage given (and absorbed) and the drugs’
endogenous anti-malarial activity. Figure 2 shows how
matched half-lives may be undermined by differences
in anti-malarial drug activity and/or if concerns over
toxicity mean the drugs must be given at different
dosages; either situation will result in a period of time
where only one drug is responsible for killing parasites
and so is in effect a monotherapy.
One way in which matching of drug killing can be
quantified is by their time above the minimal inhibitory
concentration (MIC) a concept originally used in
bacteriology but now being increasingly used in malaria
(e.g. [34] for a recent example). Time above MIC for any
anti-malarial drug is a function of the maximum concen-
tration (Cmax) and drug clearance, which are again
dependent on the dose and the formulation, and the
MIC, which is described by the PD profile. More encour-
agingly, the interaction between factors such as half-life,
dosage and parasite drug sensitivity means that a well-
designed CT could, in principle, allow for mismatch in
any of these variables by altering the relative dosages
(Figure 3) to achieve matched activity profiles post-
treatment. This does raise the interesting, and largely un-
considered, operational question of whether both
drugs should be deployed in a CT at their maximumdosages, or whether one drug may be included at a re-
duced dosage to match killing activities. The former is
probably more robust. Maximal concentrations of both
drugs optimize clinical effectiveness and help protect
against resistance being driven through drug failures
(the ‘matching’ argument only applies to selection for
resistance post-treatment [35]) and natural variation in
PK/PD may, in practice, largely undermine matching
done on average PK/PD values (see below). It is diffi-
cult to bring toxicity arguments into this discussion at
present because this is currently an under-researched area
(see below). The onset of toxicity associated with anti-
malarial drugs is generally not indicated by clinically clear
on/off signals and, moreover, an increased risk of adverse
events does not necessarily follow a direct correlation with
plasma exposure (either area under the curve, AUC, or
Cmax).
In summary, although it is essential to reiterate the
usual assertion that matching half-lives is important we
suggest it should be seen in a more subtle way and that
activity profiles after treatment are of more importance
than crude half-lives.
2. Natural variation in population PK/PD
One key operational question in CT design is the extent
to which parasites vary in their PD parameters such as
IC50. A first step in investigating the likely effectiveness of
CT design is to obtain a value for mean IC50 plus the na-
ture and extent of variation around this mean [28]. The
variation in IC50 values is critical as it determines the ex-
tent to which natural variation in PD will undermine an
idealized matched profile. Balancing half-lives, dosages
and drug sensitivity can only be plausibly done on the
Figure 2 Is it more important to match post-treatment activity profiles rather than crude drug half-lives? (A) Two drugs in a CT have
broadly similar half-lives. (B) The two drugs in the CT have very different PD profiles. (C) Multiplying concentration profiles post-treatment (shown
in (A)) by the dose-effect relationships (shown in (B)) gives a drug activity profile post-treatment; as can be seen these profiles are very different leading
one drug to persist as a vulnerable monotherapy. (D) A practical example of this effect: the drugs appear to be perfectly ‘matched’ with similar
half-lives (as in (A)) and identical kill rates (both assumed to have the ‘blue’ profile shown in (B)), but toxicity concerns means the ‘blue’
drug must be given at 2.5-fold lower dosages, leading to a severe mismatch in drug activity profiles. Note the similarities between the
results shown in (C) and (D). [Figure 2 was constructed using simple PK/PD models and their corresponding equations [26,29]. Parameter
values for the two drugs are as follows: Dose is 11 mg/kg for both in (A), (B) and (C) and 11 mg/kg for ‘blue’ and 27.5 mg/kg for ‘red’ in
(D); volume of distribution is 150 L/kg; elimination rate per day is 0.03 for ‘blue’ and 0.032 for ‘red’ (equivalent to half-lives of 23.1 and
21.7 days, respectively); maximal drug-killing rate per day (Vmax) is 3.45; IC50 is 0.044 mg/L for ‘blue’ and 0.0176 mg/L for ‘red’ in (A),(B)
and (C) and 0.044 mg/L for both in (D); slope of dose-response curve (n) is 6].
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3); in practice, the strategy will be hindered by the
huge natural variation that occurs in both PK and PD
parameters. Even if it were possible to match drug pro-
files in an ‘ideal’ human, it would appear inevitable that
natural variation in PK/PD parameters would cause a mis-
match in individual patients’ post-treatment concentration
and activity profiles and leave one drug persisting as a vul-
nerable monotherapy. The variation typically noted in
PK and PD parameters is huge. The between-subject
variability in human PK parameters is typically 30–50%
[36] while variation in parasite isolates IC50 values typi-
cally vary 100 to 10,000 fold (see, for example, Figure 3 of
[37]). Figure 4 illustrates how this variation may
undermine matching. The natural variation in PK will
be augmented by human ‘behavioural’ variation e.g. foodintake, age, nutritional status and factors such as preg-
nancy (reviewed in [38]). If these factors differentially
affect the individual drugs in the CT then mismatches
may be widened. In order to avoid amplification of the
already large between-subject variation in PK parame-
ters clear recommendations must be given on covari-
ates that affect PK such as co-administration of food
intake and dose adjustments in children under the age of
five or pregnant women. Implementing these recom-
mendations is not straightforward because providing
such advice must be balanced against the need for clear
instructions on drug use in resource-poor regions where
patients are often treated in the informal sector and may
have only casual access to anti-malarials.
It is, therefore, inevitable that mismatch will arise in
individual treatment and that mutual protection will be
Figure 3 How altering relative dosages can compensate for differences in half-live and/or endogenous anti-malarial activity. (A) The
half-lives of two drugs in this CT differ by a factor of 2, leading to one drug being left as a vulnerable monotherapy; most arguments on design
of CT end here by concluding the drugs are not well matched. (B) The drug kill rates against parasites as a function of drug concentration; they
differ in their IC50 values. (C) Compensating for differing half-lives and IC50s by increasing the dosage of drug illustrated in ‘red’ 2.5 fold: killing is
now matched and drugs provide mutual protection. [Figure 3 was constructed using simple PK/PD models and their corresponding equations
[26,29]. Parameter values for the two drugs are as follows: Dose is 75 mg/kg for ‘blue’ and 187.5 mg/kg for ‘red’; volume of distribution is 150 L/kg;
elimination rate per day is 0.05 for ‘blue’ and 0.1 for ‘red’ (equivalent to half-lives of 13.8 and 6.9 days, respectively); maximal drug-killing rate per day
(Vmax) is 3.45; IC50 is 0.088 mg/L for ‘blue’ and 0.044 mg/L for ‘red’; slope of dose-response curve (n) is 6].
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undermine the advantages of CT is uncertain although
recent PK/PD modelling suggests the selection pressures
associated with this mismatch (the ‘windows of selection’)
is likely to be much lower that currently thought [39].
Most arguments for matching half-lives are over-
optimistic and simply show a variant of Figure 1B without
considering how factors such as natural variation in
PK/PD can affect this matching. In conclusion, it is only
plausible to make approximate matches on the basis of
half-live. Most drugs outside the artemisinin class have
relatively long half-lives so could be approximately
matched with the caveats listed above.
3. Dosages and toxicity
There are two main types of toxicity associated with
malaria drugs. Those which are dose- or concentration
dependent (also referred to as ‘type A’) adverse drugreactions (ADRs), which are mostly predictable and
consistent between patients because they are explained
by the drug’s known pharmacological action. The second is
‘type B’ADRs that are generally, or at least partially, dose- or
concentration independent and which are largely unpredict-
able and dependent on an individual patient’s metabolism,
immune system or genetics. One common example for
anti-malarial drugs is glucose-6-phosphate dehydrogenase
(G6PD) deficiency which mediates toxicity in drugs from at
least two different classes, e.g. primaquine and dapsone
(Table 1). It is relatively easy to cure malaria, but curing
malaria without poisoning the patient is much more prob-
lematic. Guinea-Bissau (G-B) overcame its problem of
chloroquine (CQ) resistance by simply doubling the dos-
age of CQ given to patients. This was an effective strategy,
but raises safety concerns over toxicity (although adverse
events were not observed in practice [40]) and to date no
other country has followed this approach. One feature of
Figure 4 How natural variation in PK/PD may undermine matched post-treatment drug activity profiles. The two drugs have, on average,
the same PK/PD parameters so are perfectly matched on average, c.f. Figure 3C. In these examples, natural variation around these mean PK/PD
values results in one drug in the CT being exposed as a monotherapy for a significant period post-treatment. These illustrative differences reflect
variation in single parameters: mismatches may become much larger once simultaneously variation in all PK/PD parameters is included. (A) An
example of the impacts of differences in human PK, elimination rate; the red drug is eliminated by this patient 50% faster than the average while
the blue drug is eliminated 50% slower than the average. (B) How variation in parasites PD parameters affect these profiles: the patient has the
same PK for each drug (so concentration profiles post-treatment for both drugs are identical) but the parasites inoculated into the patient differ
in their sensitivity to the drugs: their 10-fold higher resistance (IC50) to the blue drug means the red one is effectively a monotherapy for a significant
period of time post-treatment. [Figure 4 was constructed using simple PK/PD models and their corresponding equations [22,25]. Parameter values for the
two drugs are as follows: Dose is 75 mg/kg; volume of distribution is 150 L/kg; elimination rate per day is 0.05 for ‘blue’ and 0.15 for ‘red’ (equivalent to
half-lives of 13.8 and 4.6 days, respectively); maximal drug-killing rate per day (Vmax) is 3.45; IC50 is 0.088 mg/L for ‘blue’ and 0.0088 mg/L for ‘red’; slope
of dose-response curve (n) is 6].
Hastings and Hodel Malaria Journal 2014, 13:62 Page 6 of 15
http://www.malariajournal.com/content/13/1/62current anti-malarial drugs is that their therapeutic index
(TI; the ratio between a drug’s upper ‘toxic’ and lower
‘curative’ thresholds) is very narrow (between 1.5 and 3
[41]) and only artesunate (AS) and dihydroartemisinin
(DHA) show a TI ≈ 5. This feature hinders attempts to
balance doses to obtain a matched elimination profiles
(see Figure 3C) because dosing regimens with doses ex-
ceeding the upper threshold of the target dose range are
likely to increase the number of patients experiencing type
A reactions.
Combining two drugs always increases the risk of tox-
icity, but it is important to quantify this increased risk and
to describe how it can be mitigated. The obvious assump-
tion is that risk of toxicity to the CT is additive (i.e. the
product of the risks of each drug given individually) but,
in principle, toxicity could be synergistic (i.e. the risk is
greater than twice the product) or may be antagonistic if
the presence of a drug decreases the risk of toxicity
caused by the other drug. Predicting synergy or other-
wise in drug toxicity is problematic. Laboratory studies
are vital to estimate this and, for example, animal stud-
ies showed that the teratogenic potential of the combin-
ation sulphadoxine-pyrimethamine (SP) was two-fold
higher than expected from the drugs individually (for
review see e.g. [45]). Synergy may plausibly occur if drugs
share a common toxicity mechanism e.g. in G6PD-
deficient patient, so such drugs should probably not
be combined. Synergy could also arise if drugs share
the same metabolic pathways for elimination becausecompetition for metabolizing enzymes could extend the
elimination half-life and hence the areas under the drug
concentration curve. Similarly, competition for plasma
protein binding sites could result in higher plasma drug
levels for both drugs. Note that both increased half-
lives and increased concentrations would actually in-
crease the effectiveness of the drugs so drug effective-
ness and toxicity may well be positively correlated.
One operational question in CT design is the extent to
which doses of the constituent drugs can be reduced to
lower the risk of ADRs; the reduced effectiveness of each
drug (caused by its lower dose) would be offset by the
presence of its partner drugs in the CT. For example, in
both animal and human Plasmodium infections, pyri-
methamine and sulphadoxine administered together are
curative at one-eighth the dose of either used alone [45].
An important factor in considering this strategy is that in-
creasing individual drug dosages display a law of diminish-
ing returns in terms of anti-malarial activity (Figure 5)
while increasing doses often increase the risk of toxicity
in an additive manner. Development of the promising
anti-malarial drug combination chlorproguanil-dapsone
(‘Lapdap’) plus AS was discontinued after the drug
showed G6PD-associated toxicity in Phase 3 clinical trials
[46]. It is believed that dapsone was responsible for the
toxicity and it remains a possibility that the CT could
be re-evaluated by reducing dapsone dosages to reduce
toxicity and relying on artesunate to offset the reduced
therapeutic effects of the lower dapsone dose. Such a
Table 1 Currently available classes of anti-malarial drugs
Drug class Example drugs Comments
Artemisinins
(or artemisinin derivatives)
Artesunate, artemether and
dihydroartemisinin
The most widely used of the anti-malarial drugs with very short
half-lives. These are sub-curative in standard 3 day regimens if
used as monotherapies
Antifolates Pyrimethamine, chlorproguanil,
proguanil, sulphadoxine and dapsone
The combination sulphadoxine-pyrimethamine (SP; also known
by its trade name ‘Fansidar’) is widely used for therapy. Both
constituents have long half-lives so it was given as a single-dose
regimen but resistance quickly evolved. Its use is now primarily
restricted to treatment/prophylaxis in intermittent treatment
programmes
4-aminoquinolines Chloroquine, amodiaquine, piperaquine,
pyronaridine and naphthoquine
Chloroquine was used in huge quantities as a monotherapy for
over 30 years. Resistance occurred only infrequently and Africa
never developed its own resistance instead it was aquired by
immigrations from South-East Asia [42].
Arylamino alcohols Quinine, mefloquine, lumefantrine
and halofantrine
Quinine was the first anti-malarial to be identified. A long
treatment duration and its safety profile means it is now mainly
used in early pregnancy or as a (parenteral) second-line treatment
either alone or in combination in uncomplicated or severe malaria.
Lumefantrine with artemether is currently the most widely used
anti-malarial combination therapy; it has low-level antagonistic
resistance with chloroquine [43].
Naphthalenes Atovaquone Atovaquone is active against hepatic and asexual stages but
resistance arises spontaneously at very high rates. Has synergistic
pharmacodynamics when combined with proguanil, resistance
no longer occurs at high rates and the combination therapy
widely used as prophylaxis under the trade-name ‘Malarone’.
Can also be used curatively but high cost restricts its deployment
in resource-poor health services.
8-aminoquinolines Primaquine and tafenoquine These drugs affect hepatic and transmission stages but do not
affect the pathogenic asexual stages of the plasmodium cycle
so are not routinely uses to cure acute infections. Both are toxic
in glucose-6-phosphate dehydrogenase deficient patients [44].
Primaquine has a short half-life which reduces its therapeutic
effectiveness but means concentration can be allowed to drop
very rapidly in patients identified with adverse reactions.
Antibiotics Tetracycline These drugs do have activity against the asexual stages but
their slow speed of action precludes their use as therapeutics
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PK/PD modelling of its efficacy, which could simulta-
neously investigate how the reduced-dose CT would
by threatened by, and possibly drive, the spread of
resistance [28].
4. Do the drugs have independent pharmacodynamics?
Drugs within a CT may act additively, synergistically or
antagonistically in their ability to kill malaria parasites.
Chou [47] noted that the definition of synergy is fraught
with difficulty and misunderstanding and readers should
view this paper for a full discussion. A simple intuitive
approach can be used in this context where synergy is
an action greater than the sum of the two drugs used
separately and antagonism occurs where the two drugs
have less anti-malarial activity than would be expected
from their individual activities. Synergy/antagonism in
PD effects is often detected in vitro through construction
of isobolograms, which quantify how parasite killing or
growth inhibition depends on the concentrations of both
drugs in a combination [48-51].It would be expected intuitively that drugs with the
same mode of action would be largely antagonistic.
For example, if a drug completely blocks the haem
polymerization pathway then there would appear little
point in combining it with another haem-inhibiting
drugs and blocking it twice. Similarly artemisinins are
converted to their active metabolite DHA in vivo, and
presumably both forms have the same target; it would
be probably wrong to regard both forms as having inde-
pendent PD (see discussion in [28]).
An alternative ‘intuitive’ expectation is that using two
drugs with the same mode of action would be additive
and, crudely, would have double the effect of either one
alone; this is consistent with the fact that all anti-
malarial drugs so far deployed have had their dosages in-
creased to improve effectiveness. In fact, the reverse is
probably true: PK/PD arguments suggest that increasing
dosages will suffer from a law of diminishing returns if
drugs share the same mode of action; see Figure 5. In es-
sence, increasing the dose of the same drug extends the
duration of effect, rather than it magnitude (Figure 5) if
Figure 5 The Law of Diminishing Returns when increasing drug dosages. This example is based on piperaquine using PK/PD parameters
from Table 1 of Winter & Hastings [25]. (A) The drug concentrations post-treatment: the green line is the standard dose of three daily doses of
18 mg/kg given as a single dose of 54 mg/kg (for illustrative purposes), the blue line is a double dose (108 mg/kg), and the red line is a triple
dose (162 mg/kg). (B) The Michaelis-Menton relationship between drug concentration and anti-malarial activity. (C) The activity profiles
post-treatment of the three different doses, obtained by multiplying the drug concentrations by their killing rate. Doubling the dose gave
only an extra 49% area under the drug killing curve while tripling the dose gave only an increase of 19% compared to the double dose. [Figure 5
was constructed using simple PK/PD models and their corresponding equations [26,29]. Parameter values for the three drugs are as follows: Dose is
54 mg/kg for ‘green’, 108 mg/kg for ‘blue’ and 162 mg/kg for ‘red’; volume of distribution is150 L/kg; elimination rate per day is 0.03 (equivalent to
half-life of 23.1 days); maximal drug-killing rate per day (Vmax) is 3.45; IC50 is 0.088 mg/L; slope of dose-response curve (n) is 6].
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the drug with the longest post-treatment activity (see
Figure 3) will be the main determinant of therapeutic
outcome and its partner’s contribution may be small to
negligible. Diminished returns may still be operationally
useful, for example the additional 49% parasite killing asso-
ciated with the example on Figure 5 may still be enough to
restore drug efficacy, but it does not necessarily repre-
sent best use of drugs within a CT, hence the usual ad-
vice to avoid combining drugs with the same mode of
actions (e.g. [32,52]). The law of diminishing returns
may lead to a practical problem of a potential single dose
cure [17,32]. While a single dose regimen might be a real
game changer from a patient adherence perspective, the
single dose needed to achieve the same extent of killing
might, for example, lead to an inacceptable high Cmax, or
the physical tablet size might make it impossible for pa-
tients to swallow it.Combining drugs with additive or synergistic action
should also increase parasite clearance post-treatment and
hence may speed the resolution of symptoms. This is obvi-
ously desirable but much less important, certainly from a
resistance standpoint, than whether a patient is actually
cured. Clearance post-treatment is also complicated in
anti-malarials because it is mainly determined by the
fastest acting drug, invariable an artemisinin, in ACT.
Artemisinins have a short half-live and show stage spe-
cific killing so clearance rate is also affected by the malaria
parasite stages that predominate at the time of treatment.
Clearance is also complicated by patient immune status
[53,54], with immune patients clearing parasites more
rapidly.
One potential drawback of synergy is that the inter-
dependency between the drugs means that if resistance
evolves to one individual component then the CT may
start to fail. The best-known example is SP where early
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P. falciparum dihydrofolate reductase gene (pfdhfr) that en-
codes resistance to pyrimethamine. Sulphadoxine is unable
to clear infections unaided by pyrimethamine and the CT
as a whole started to fail once resistance to pyrimethamine
started to evolve [55,56]. The theoretical basis for CT rests
on the assumption that mutations in two or more genes
are required to encode resistance to the CT. SP fails this
design principle and hence the malaria community does
not generally regard SP as a ‘true’ CT because, oper-
ationally, it behaves as monotherapy with mutations in a
single gene capable of encoding resistance to treatment.
The SP example illustrates a very important and often
overlooked design principle: synergy between drugs in a
CT is obviously beneficial but should not be used a reason
to reduce individual drug dosages in the CT, except as a
strategy to reduce concerns over toxicity (see above).
Ideally each drug should be deployed at dosages that
would be required for it to be effective as monotherapy
so that the CT remains effective even when resistance is
present to one of the components.
5. Do the drugs have independent pharmacokinetics?
Pharmacokinetic processes are often non-independent and/
or saturable so one consideration of CT design is the
extent to which individual drug PK are affected by co-
administration with their partner drugs. For example,
lumefantrine (LF) absorption appears to saturate, so
lower doses given more often is more effective [57];
drugs sharing the same absorption route as LF could
compete for absorption and hence be antagonistic
which would reduce their efficacy within a CT. If drugs
share the same conversion or elimination pathways
post-absorption then their actions could become non-
additive but in unpredictable ways. For example, if con-
version to an active form is impaired by the presence
of a partner drug, and the unconverted form is elimi-
nated while awaiting conversion, then drug PK may be
antagonistic. Conversely, if the same elimination pathway
saturates for both drugs, and both parent forms are active,
then drug half-lives may be extended and anti-malarial
synergy may arise.
There appears to be little literature on the interactions
between PK of anti-malarial drugs. However, the pres-
ence and importance of PK drug interactions is demon-
strated by the much better characterized examples of
interactions between drugs co-administered to treat dif-
ferent diseases. A recent review by Sousa et al. [58]
stated that “Rifampicin, a standard component of com-
bination regimens for treating TB, has a great influence
on the bioavailability and the efficacy of several anti-
malarial drugs, not only because of the inhibition of
Phase I and II enzymes of hepatic metabolism, but
also because of its effect on drug absorption anddistribution. It induces almost all cytochrome P450
(CYP) enzymes, it inhibits N-acetyltransferases and
it alters the expression of membrane transporters.”
Malaria and HIV are co-endemic and there are detailed
examples of how co-administration of anti-malarials
and anti-retrovirals affects each other’s PK, many of
which can be explained by the metabolic properties (i.e.
induction or inhibition) of the co-administered drugs (re-
cently reviewed by [59]). One class of anti-HIV drug are
the protease inhibitors (PIs) which tend to increase expos-
ure (defined as area under the plasma concentration–
time curve and/or maximum concentration; for details see
Tables 1 and 2 in [59]) of LF and decrease the exposures
of artemether (AM) and DHA. Another class, the non-
nucleoside reverse transcriptase inhibitors (NNRTIs), tend
to decrease the exposures of AM, DHA and LF, when co-
administered with AM-LF [59]. Fewer studies character-
ized the effects of PIs or NNRTIs on AS combinations,
where nevirapine (a NNRTI) increased AS exposure and
ritonavir (a PI) decreased DHA exposure. These interac-
tions may be mutual: AM-LF or AS combinations had lit-
tle effect on the PK of HIV-anti-retrovirals, although AM-
LF resulted in decreased nevirapine exposure and
pyronaridine-AS increased ritonavir exposure [59]. It is
therefore certainly plausible that drugs in an anti-
malarial CT can induce or inhibit each other’s metabol-
ism. Artemisinins drugs are potential inducers of CYP en-
zymes, and the most inducible are CYP2B6 and CYP3A4,
which are believed to be the main enzymes involved in
the auto-induction of artemisinin drugs [60]. In a pooled
PK analysis the onset of auto-induction for artemisinin
was found to be very rapid, e.g. 8 h after the first dose
[61]. This implies that a single dose of artemisinin is
capable of enzyme induction. The analysis suggested auto-
induction has minor effects on the systemic clearance of
artemisinin but results in a 13-fold decrease in its bioavail-
ability. The metabolism of drugs is also affected by regional
differences in the prevalence of anti-malarial drug-
metabolizing enzyme polymorphisms (for a detailed dis-
cussion see [62]) which further complicate the link be-
tween drug dosage and subsequent anti-malarial drug
concentration and treatment outcome.
In essence, the consequences of PK interactions are diffi-
cult to predict and depend on the exact metabolic pathways
and whether or not active metabolites contribute to parasite
killing. One big advantage over the other factors enumerated
here is that PK interactions can be measured in preclinical
studies and clinical (Phase I) studies of CT development in
healthy human volunteers. Pharmacokinetic parameters of
anti-malarial drugs are known to be affected by malaria
infections (e.g. quinine clearance is reduced in acute
malaria, primarily as a result of disease-induced dysfunc-
tion in hepatic mixed-function oxidase activity [63]) so the
Phase I study results are not definitive, but have the huge
Table 2 An ideal Target Product Profile (TPP) for an anti-malarial combination therapy
Property Attribute Reference
Formulation & dose Single-dose treatment regimen Desirable [17,32]
Stable Critical [32]
Fixed-dose in a single formulation Desirable [32]
Orally, rectally and parentally applicable Desirable [32]
Dose of each drug high enough so that it will remain
effective even if resistance is present to the other drug
Critical This manuscript KPC#4
Mode of action Effective against all stages of parasite development
in the human host
Desirable [32]
Active against hypnozoites and able to prevent relapse Desirable [17]
Transmission-blocking activity Desirable [17]
Robust to the evolution of resistance Critical [32]
Independent, or preferably synergistic, mode of action of drugs Desirable [32]; this manuscript KPC#4
Different metabolic target(s) of drug action Desirable/Critical This manuscript KPC#4
Negative patterns of cross resistance Desirable This manuscript KPC#6
Pharmacokinetics &
pharmacodynamics
(PK/PD)
Elimination half-lives of drugs should be approximately matched Desirable [32,33]
The post-treatment drug activity profiles (based on elimination
half-lives, dosages and drug sensitivity) should be matched
Critical This manuscript KPC#1
(Figures 2 & 3)
Low levels of inter-individual PK/PD variation to minimise
drug activity profile mismatch in individual infections
Desirable This manuscript KPC#2
(Figure 4)
Extended period of chemoprophylaxis post-treatment Desirable [15,17]
Predictable metabolism via non polymorphic enzymes Desirable This manuscript KPC#5
No pharmacokinetic drug-drug interaction Desirable This manuscript KPC#5
Efficacy & safety Large therapeutic index Desirable This manuscript KPC#3
Toxicity of drugs should be additive or antagonistic Desirable This manuscript KPC#3
Drug conversion and elimination should not share same
metabolic pathway
Desirable This manuscript KPC#3
Dissimilar type B adverse drug reaction profiles Desirable This manuscript KPC#3
Safe and well-tolerated Critical [32]
Efficacious and effective Critical [32]
Cost Affordable/cheap Critical [17,32]
KPC: key pharmacological consideration.
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raise a whole series of ethical issues based around the
rights of patients to receive current local best standard of
care.
6. Do the drugs share common mechanisms of cross
resistance?
The benefits of using a CT rest on the parasite popula-
tion having to evolve resistance to both drugs to survive
treatment with the CT (see above). Intuitively, cross-
resistance between the constituent drugs in a CT will
undermine this effect and modelling shows that even
small amounts of cross resistance may significantly re-
duce the expected therapeutic lifespan of both drugs [64].
The clearest example of cross-resistance in anti-malarials
occurs in the antifolates class. The two best-knownantifolate combinations are SP and chlorproguanil-
dapsone. Sulphadoxine and dapsone both inhibit P. fal-
ciparum dihydropteroate synthase (PfDHPS) while
pyrimethamine and chlorcycloguanil, the active me-
tabolite of chlorproguanil, both inhibit P. falciparum dihy-
drofolate reductase (PfDHFR). Parasites carrying single-
point mutations in the pfdhfr gene showed decreased
sensitivity towards pyrimethamine, rising from 10-fold as-
sociated with a single mutations to 1,000-fold associated
with a quadruple-mutant allele [65]. Similarly, parasites
that have accumulated several mutations in the pfdhps
gene display resistance towards sulphadoxine [66].
While the so-called ‘triple mutant’ with point muta-
tions at codons 108, 51 and 59 of the pfdhfr gene is re-
sistant against pyrimethamine and sensitive to
chlorcycloguanil, the additional PfDHFR mutation at
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[67]. The obvious question is the extent to which this
paradigm of cross-resistance in antifolates is likely to ex-
tend to the other classes and it is useful, in this context
to examine the lessons learnt from the evolution of in-
secticide resistance. Researchers in this field have noted
a dichotomy in resistance mechanisms (e.g. [68]). ‘Target
site’ resistance arises when mutations in the insecticide
target site disrupt binding of the insecticide to its tar-
get, usually an enzyme. The second mechanism is
‘metabolic resistance’ where mutations disrupt the ability
of an insecticide to reach, or accumulate in, its target
site; typical mechanisms are metabolic detoxification of
the insecticide or cell pumping mechanism that prevent
insecticide accumulating at its target and these mech-
anism are usually associated with changes in expres-
sion levels of genes in the adenosine triphosphate-
binding cassette (ABC) transporters and CYP gene
families [69]. The main mechanism of resistance to
anti-malarial antifolates appears to be target site resistance
in the pfdhfr and pfdhps genes but known mechanisms of
resistance to CQ, mefloquine (MQ) and LF are meta-
bolic and involve mutations and/or copy number vari-
ation in the P. falciparum chloroquine resistance
transporter (pfcrt) and multiple drug resistance
protein-1 (pfmdr1) genes both of which encode cell mem-
brane transporters. Cross resistance in this case is more
likely to depend on the chemical structure and ionic
charge of the drug than on its eventual target site [70].
This may explain why, for example, mutations in the pfcrt
gene decrease resistance to LF while increasing re-
sistance to CQ. Both drugs are in the same class
(Table 1) but their structure means that they are
recognized differentially by the cell transporter mech-
anism. Similarly Basco & Ringwald [71] demonstrated that
piperaquine (PPQ) remains active against CQ-resistant par-
asites. These drugs are both 4-aminoquinolines (Table 1)
and their close structural similarity suggests they would
have the same mode of action, but these observations sug-
gest there are different mechanisms of resistance, presum-
ably through ‘metabolic resistance’, to the different drugs. In
summary, many non-antifolate anti-malarial drugs disrupt
the process of haem crystallization so target a physio-
chemical process rather than having a specific enzyme tar-
get site. The absence of a definite, parasite-encoded target
molecule for such drugs makes it highly likely that meta-
bolic, rather than target-site, resistance is the main
mechanisms of resistance which means the chances of
cross-resistance, even within drugs in the same class, are
greatly diminished.
Cross resistance can be quantified as a correlation be-
tween IC50 observed in field and/or laboratory isolates.
As a recent example, Mu and colleagues [37] measured
the in vitro drug sensitivity (i.e. IC50s) of 185 field isolatesto seven drugs from four different classes. They reported
the correlation between IC50s to different drugs (their
Figure 3). The results were interesting: correlations were
generally weak with correlation coefficients typically
around -0.2 to 0.4, but were not closely dependent on the
class of origin of the drugs. In fact, the two drugs with the
strongest correlation in IC50 came from two separate
classes, the artemisinin derivative DHA, and the arylamino
alcohol MQ (Table 1). In addition, there may be far less di-
versity in resistance mechanisms than might be antici-
pated: Yuan et al. [72] screened a library of 2,811 chemical
compounds for anti-malarial activity, identified 32 highly
active compounds and then tested them in 61 parasite iso-
lates. They found that three resistance loci, pfcrt, pfdhfr,
pfmdr1 were involved in 96% of cases where there was
significant variation in isolate drug sensitivity.
One caveat associated with such data obtained from
field isolates is that the IC50s may reflect the effects of
standing genetic variation at many loci as a kind of
‘baseline’ drug sensitivity before high-level resistance arises
through individual mutations with large effects. There is no
guarantee that the same correlations in IC50s noted from
field isolates will be associated with individual mutations
that have major effects of drug sensitivity. Data are limited
on this and, to date, the only clear example is that of the
pfcrt K76T mutation which increases resistance to CQ but
appears to only slightly increase sensitivity to LF [43]. See
Ecker and colleagues [73] for a more detailed discussion of
how single mutations affect drug sensitivity in general and
in the best known case of pfcrt and CQ resistance [74].
It is often recommended that combining drugs from
same class into a CT should be avoided (e.g. [32,41]) and
the usual reasoning is because a mutation may occur
that encode cross-resistance to members of the class
(and thence the two drugs in the CT). This would be
undesirable but, with the exception of antifolates, such
mutations have not been observed. Far more serious is
the fact that drugs in the same class probably share the
same mechanism of parasites killing and, possibly, mecha-
nisms of human toxicity; these latter two factors are likely
to be of more immediate concern in CT design than the
longer term threat of resistance.
Target product profiles for combination therapies
The development of new products may be informed by
clearly identifying the desired properties of the final
product, the Target Product Profile (TPP). One problem
with TPPs is that they often constitute an idealized, but
often unattainable, ‘wish list’ of what is required of a
product; with this caveat, such a TPP is presented in
Table 2 which builds on previous work presented by
Kremsner and Krishna [32] and Burrows et al. [17] by
incorporating the pharmacological considerations dis-
cussed above. There is unlikely to be a CT that fulfils all
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lem is to trade-off the different characteristics offered by
different formulations of CTs. This review has attempted
to identify and quantify several key design principles in
order to facilitate choice of CT design in a real world
where no perfect CT is likely to exist in the medium to
long term. The PK/PD arguments discussed above sug-
gest the TPP for an ideal CT should include the follow-
ing properties: the two drugs should act synergistically,
have independent PK, have independent actions on tox-
icity, have negative patterns of cross resistance and
have post-treatment drug activity profiles that can be
matched. Importantly all these criteria are relatively
easy to measure in culture (drug PD synergy, basal
levels of cross resistance) or in preclinical work in
animals (toxicity) and early clinical work in humans
(PK, toxicity).
The problem is that there are only a limited number
of existing forms of anti-malarials and design of new
CTs may not be able to meet this TPP in the near future.
A CT may not be ideal, but may still be useful because,
importantly, even a CT that falls well outside that TPP
can still be highly beneficial as the following success
story illustrates; following Chou [47], the codes A and B
are used for the two drugs. Drug A was failing badly, so
was combined with Drug B. The match to the TPP was
weak: high levels of cross resistance occurred, toxicity
was additive, and drug activity follows a law of diminish-
ing returns although and, more encouragingly, half-lives
were matched. Drug A was CQ and Drug B was also
CQ: as described above, Guinea-Bissau circumvented its
problem of CQ resistance by the simple (although po-
tentially toxic) expedient of doubling the dose of CQ
given to patients to get a highly effective ‘CT’ [75]. This
perfectly illustrates that it is possible to get a highly ef-
fective ‘CT’, capable of overcoming even high levels of
resistance, by combining drugs within the same class
even with 100% levels of cross resistance. The G-B story
thereby illustrates an important design principle: that
desirable and undesirable factors in a TPP can be listed
but the ultimate test must be how a CT performs in the
clinic. The CQ + CQ ‘CT’ violates all of the principles
discussed above but its increased efficacy appears suffi-
cient to eliminate parasites which are resistant to stand-
ard doses of CQ. The reason the G-B policy has not
been widely copied is potential toxicity. The TIs of anti-
malarials are relatively small (see above) and there is the
additional operational requirement that drugs be de-
ployed to dose according to weight/age/height bands
within which heavy patients receive relatively low doses
and light people receive higher, potentially toxic doses
[30], and it is easy to see why policy makers are reluctant
to follow the G-B strategy. The primary requirement is
therefore that the two drugs are antagonistic, or atleast not synergistic, in causing toxicity. The biggest
operational decision in CT design is to decide whether
to use the maximum dosages of each drug in a CT for
the largest clinical effect and long-term robustness
against resistance, or whether to reduce the dosages to
reduce the risk of toxicity and hence maximize the
short-term objective of ensuring safety and clinical
approval.
One obvious question is whether triple- or even
quadruple-combinations (as used to treat TB and HIV)
could help meet the criteria of TPP. One obvious benefit
for anti-malarials is that adding another longer half-life
drug would partially remove the currently very large mis-
match in periods of killing between the artemisinins and
their typical partner drugs. In general, the more compo-
nents, the more clinically effective the treatment is likely
to be (for the reasons outlined above), but the obvious
drawbacks are the increased cost, the possibility of more
complicated regimes (which can affect patient adherence)
and the increased risks of toxicity. The rationale design of
such triple- or quadruple combinations can be guided by
the design principles outlined above. One example of a
currently-proposed triple combination anti-malarial is to
add primaquine (PQ) to current ACT [76]. The important
feature of these combinations is their mutually exclu-
sive PD: ACT targets the asexual and early stage ga-
metocytes while PQ targets mature gametocytes. This
means that arguments based on matching PK/killing
and independent/synergistic PD can be ignored and the
combination evaluated on the basis of drug interaction in
toxicity, interference between individual drugs’ PK and,
possibly, mechanism of cross-resistance. These factors can
then be weighed against the value of PQ in reducing mal-
aria transmission.
Conclusions
Maintaining a pipeline of effective anti-malarial drugs is a
public health priority clearly recognized by the inter-
national community which supports the Medicines for
Malaria Venture (MMV) to co-ordinate the research and
development (R&D) pipeline of such drugs. The pipeline
is relatively healthy [15] but the drug development pro-
cess is slow and inherently unpredictable. MMV have a
strategy for prioritizing development [17,77] but this
unpredictability also places a responsibility on the R&D
community for good stewardship and use of existing and
newly-developed drugs. This is mainly achieved through
their deployment as CTs to minimize the risk of resistance
arising, and to maintain their long-term effectiveness. In
most models of drug resistance, the ‘resistance’ trait is
modelled as a purely parasite trait that determines whet-
her or not the infection will be cleared by drug treatment.
A PK/PD mechanism-based approach explicitly recognizes
that drug ‘resistance’ (usually expressed as an increased
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(12 parameters for two-drug CTs) that determine a pa-
tient’s therapeutic outcome. In essence, it is necessary to
understand how CTs successfully clear infections before
starting to understand how, why and when individual pa-
tients fail treatment. Placing resistance in this context
therefore reveals the pharmacological principles that de-
termine what makes a ‘good’ CT and how the threat of re-
sistance can be minimized in this context. It is argued
herein that adopting a rational and objective method to
simulate CT drug effectiveness using PK/PD principles
can play a valuable role in this process.
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